AbbVie Presents Optimistic Take For 2020, Expects Quick Recovery For Botox Aesthetic

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

AbbVie made only a slight adjustment to its earnings-per-share guidance despite expected Q2 downturn due to the pandemic. It sees Allergan’s aesthetic business as bouncing back quickly.

Stone / United Kingdom - February 12 2020: Abbvie biopharmaceutical company logo seen on the brochure with the viral masks, syringe and pills. Concept photo. Selective focus.
AbbVie says its merger with Allergan likely will close in May

AbbVie Inc. gave a mostly optimistic presentation during its first quarter earnings call on 1 May despite the tumultuous business conditions caused by the COVID-19 pandemic – the Chicago area firm even increased sales guidance for Skyrizi as that drug’s strong launch continues. CEO Rick Gonzalez also provided a detailed explanation of why AbbVie thinks Allergan PLC’s aesthetic business, led by Botox, will recover quickly from pandemic-related effects.

AbbVie’s revenues grew by 10.7% operationally (factoring in foreign exchange) during the first quarter to nearly $8.62bn, with little negative...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.